Trial data keep BioSphere on track for UFE (uterine fibroid embolisation) filing
This article was originally published in Clinica
BioSphere Medical says it is on track to submit its microspheres for uterine fibroid embolisation (UFE) to the US FDA by the second quarter of 2002, following favourable results from a phase II trial of the product. The product will be aimed at the six million women who seek treatment for uterine fibroids annually in the US.
You may also be interested in...
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.